Valeritas

Valeritas

Improving health and simplifying life for people with diabetes.

Founded 2006

Bridgewater, United States 35 employees Venture round Total: $355.00M Biotechnology, Health Care +1

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go Wearable Insulin Delivery Device, is designed to help patients with Type 2 diabetes in managing their insulin levels. This small, discreet, and easy-to-use device delivers continuous subcutaneous insulin infusion over 24 hours, along with on-demand bolus dosing, enabling patients to closely mimic the body’s normal physiologic pattern of insulin delivery. The company, founded in 2006, operates in the Biotechnology and Health Care sectors and is headquartered in the United States. The most recent Venture Round investment was received on 04 May 2016 from CRG and Montrose Capital Partners. Overall, Valeritas’ focus on improving the lives of diabetes patients through innovative medical technology, along with their successful commercialization of the V-Go device and significant real-world analyses confirming its efficacy, positions the company as an attractive investment opportunity in the biotechnology and healthcare industries. As of the most recent investment round in 2016, the company continues to demonstrate potential for growth and impact in the market, particularly as it holds commercial clearance in the United States and the E.U.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	Undisclosed	2	CRG, Montrose Capital Partners	04 May 2016
Series D	$45.00M	7	Kaiser Permanente Ventures, MPM Capital +5	11 Jul 2014
Debt Financing	$100.00M	1	CRG	04 Jun 2013
Series C	$150.00M	10	Kaiser Permanente Ventures, MPM Capital +8	12 Sep 2011
Series B	$10.00M	-		01 Apr 2011
Series A	$50.00M	7	MPM Capital, Pitango Venture Capital +5	10 Sep 2008

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

Undisclosed

CRG, Montrose Capital Partners

04 May 2016

Series D

$45.00M

Kaiser Permanente Ventures, MPM Capital +5

11 Jul 2014

Debt Financing

$100.00M

CRG

04 Jun 2013

Series C

$150.00M

Kaiser Permanente Ventures, MPM Capital +8

12 Sep 2011

Series B

$10.00M

01 Apr 2011

Series A

$50.00M

MPM Capital, Pitango Venture Capital +5

10 Sep 2008

FAQ About Valeritas

Improving health and simplifying life for people with diabetes.

Valeritas was founded in 2006.

Valeritas is headquartered in Bridgewater, United States.

Valeritas operates in Biotechnology, Health Care and Medical Devices. Its work centres on diabetes management, insulin delivery, V-Go and h-Patch technology.

Valeritas has approximately 35 employees.

Valeritas has completed 6 funding rounds, raising a total of $355.00M. The latest funding stage is Venture round.

Top alternatives and competitors to Valeritas include CeQur, Beta Bionics, MicroTech Medical, Diatech Diabetes, Inc., Zenomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Valeritas and CeQur are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Valeritas

Funding Rounds & Investors (6)

Valeritas Alternatives & Competitors

FAQ About Valeritas